Following the first official announcement at the beginning of December last year, Hyris completed the transfer of its shares into Ulisse Biomed via a reverse take-over transaction. The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.
Read Press ReleasePillSafe® protects the patient with a patented, innovative pill distribution control system that improves dosage safety, prevents prescription drug misuse, and provides potential solutions for the national opioid epidemic.
Read Press ReleaseCardiff Advisory Managing Partner Has Decades of Experience Guiding Life Sciences and Healthcare Companies Through Pivotal Growth, Won the Alzheimer’s Association of San Diego 2023 Hope Award and Has Been Recognized as One of San Diego’s 500 Most Influential People for the Last Four Years
Read Press ReleaseTune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment of Parkinson’s disease.
Read Press ReleaseWith $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a one-two punch to combat BRAF-mutated colorectal cancer and its “dismal prognosis.”
Read Press ReleaseNew innovative clinical services to help pharmaceutical and biotech companies improve patient recruitment, reduce the risk of adverse reactions, and refine the drug development process.
Read Press ReleaseLatham BioPharm Group, part of SIA Partners, today announced receiving a new Indefinite Delivery, Indefinite Quantity (IDIQ) contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), titled Preclinical Services for Biopharmaceuticals Product Development.
Read Press ReleaseComplimentary Workshop to Provide Expert Insight and Strategies for Regulatory Affairs Specialists, Pharmaceutical Enthusiasts and Drug Developers
Read Press ReleaseManuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function.
Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m. in San Diego entitled “Novel stem cell-derived islet-like clusters potently control rodent blood glycemia”.
Seraxis will be taking meetings at BIO-Europe, November 6-8, in Munich.
Former site of US Compounding is acquired by up-and-comer in custom compounded pharmaceuticals, FarmaKeio, as part of ongoing expansion to support availability and delivery of custom compounded medications nationwide.
Read Press ReleaseCommonsense Online and Mobile Approach to Identifying and Engaging With Drug Manufacturers to Meet DSCSA Requirements — Including Drop Shipment Transactions
Read Press ReleaseNew biologics outsourcing solution provider leverages proven track record of Tanvex BioPharma USA Inc. to help early-stage companies bring mammalian and microbial derived biologics from concept to commercialization.
Read Press Release